|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DYNC2LI1 |
Gene summary for DYNC2LI1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DYNC2LI1 | Gene ID | 51626 |
| Gene name | dynein cytoplasmic 2 light intermediate chain 1 | |
| Gene Alias | CGI-60 | |
| Cytomap | 2p21 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q8TCX1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51626 | DYNC2LI1 | LZE3D | Human | Esophagus | HGIN | 5.92e-03 | 5.11e-01 | 0.0668 |
| 51626 | DYNC2LI1 | LZE4T | Human | Esophagus | ESCC | 1.42e-05 | 1.48e-01 | 0.0811 |
| 51626 | DYNC2LI1 | LZE7T | Human | Esophagus | ESCC | 1.01e-04 | 3.25e-01 | 0.0667 |
| 51626 | DYNC2LI1 | LZE24T | Human | Esophagus | ESCC | 3.89e-11 | 3.35e-01 | 0.0596 |
| 51626 | DYNC2LI1 | LZE21T | Human | Esophagus | ESCC | 1.89e-02 | 1.79e-01 | 0.0655 |
| 51626 | DYNC2LI1 | P1T-E | Human | Esophagus | ESCC | 4.07e-05 | 2.74e-01 | 0.0875 |
| 51626 | DYNC2LI1 | P2T-E | Human | Esophagus | ESCC | 1.19e-37 | 6.92e-01 | 0.1177 |
| 51626 | DYNC2LI1 | P4T-E | Human | Esophagus | ESCC | 2.19e-18 | 4.90e-01 | 0.1323 |
| 51626 | DYNC2LI1 | P5T-E | Human | Esophagus | ESCC | 1.56e-19 | 3.74e-01 | 0.1327 |
| 51626 | DYNC2LI1 | P8T-E | Human | Esophagus | ESCC | 7.64e-19 | 2.83e-01 | 0.0889 |
| 51626 | DYNC2LI1 | P9T-E | Human | Esophagus | ESCC | 3.52e-07 | 1.60e-01 | 0.1131 |
| 51626 | DYNC2LI1 | P10T-E | Human | Esophagus | ESCC | 2.74e-17 | 3.57e-01 | 0.116 |
| 51626 | DYNC2LI1 | P11T-E | Human | Esophagus | ESCC | 1.97e-11 | 3.41e-01 | 0.1426 |
| 51626 | DYNC2LI1 | P12T-E | Human | Esophagus | ESCC | 9.41e-13 | 2.93e-01 | 0.1122 |
| 51626 | DYNC2LI1 | P15T-E | Human | Esophagus | ESCC | 4.31e-10 | 1.94e-01 | 0.1149 |
| 51626 | DYNC2LI1 | P16T-E | Human | Esophagus | ESCC | 2.64e-25 | 5.00e-01 | 0.1153 |
| 51626 | DYNC2LI1 | P17T-E | Human | Esophagus | ESCC | 1.90e-03 | 1.95e-01 | 0.1278 |
| 51626 | DYNC2LI1 | P20T-E | Human | Esophagus | ESCC | 1.14e-08 | 2.28e-01 | 0.1124 |
| 51626 | DYNC2LI1 | P21T-E | Human | Esophagus | ESCC | 4.08e-16 | 3.07e-01 | 0.1617 |
| 51626 | DYNC2LI1 | P22T-E | Human | Esophagus | ESCC | 2.04e-33 | 6.16e-01 | 0.1236 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003070518 | Esophagus | ESCC | cytoskeleton-dependent intracellular transport | 133/8552 | 195/18723 | 1.48e-10 | 4.27e-09 | 133 |
| GO:001097013 | Esophagus | ESCC | transport along microtubule | 107/8552 | 155/18723 | 3.17e-09 | 6.80e-08 | 107 |
| GO:003150314 | Esophagus | ESCC | protein-containing complex localization | 139/8552 | 220/18723 | 1.14e-07 | 1.85e-06 | 139 |
| GO:190211514 | Esophagus | ESCC | regulation of organelle assembly | 116/8552 | 186/18723 | 3.15e-06 | 3.53e-05 | 116 |
| GO:00991114 | Esophagus | ESCC | microtubule-based transport | 115/8552 | 190/18723 | 2.54e-05 | 2.15e-04 | 115 |
| GO:006049118 | Esophagus | ESCC | regulation of cell projection assembly | 110/8552 | 188/18723 | 2.60e-04 | 1.58e-03 | 110 |
| GO:012003218 | Esophagus | ESCC | regulation of plasma membrane bounded cell projection assembly | 108/8552 | 186/18723 | 4.37e-04 | 2.46e-03 | 108 |
| GO:19021155 | Oral cavity | OSCC | regulation of organelle assembly | 109/7305 | 186/18723 | 4.54e-08 | 8.45e-07 | 109 |
| GO:003070510 | Oral cavity | OSCC | cytoskeleton-dependent intracellular transport | 113/7305 | 195/18723 | 6.03e-08 | 1.09e-06 | 113 |
| GO:00315034 | Oral cavity | OSCC | protein-containing complex localization | 123/7305 | 220/18723 | 2.54e-07 | 4.00e-06 | 123 |
| GO:00109706 | Oral cavity | OSCC | transport along microtubule | 88/7305 | 155/18723 | 5.35e-06 | 6.02e-05 | 88 |
| GO:006049110 | Oral cavity | OSCC | regulation of cell projection assembly | 100/7305 | 188/18723 | 5.27e-05 | 4.38e-04 | 100 |
| GO:012003216 | Oral cavity | OSCC | regulation of plasma membrane bounded cell projection assembly | 98/7305 | 186/18723 | 1.00e-04 | 7.54e-04 | 98 |
| GO:00991113 | Oral cavity | OSCC | microtubule-based transport | 96/7305 | 190/18723 | 7.92e-04 | 4.27e-03 | 96 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05132211 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
| hsa0496223 | Esophagus | ESCC | Vasopressin-regulated water reabsorption | 33/4205 | 44/8465 | 5.27e-04 | 1.78e-03 | 9.13e-04 | 33 |
| hsa05132310 | Esophagus | ESCC | Salmonella infection | 191/4205 | 249/8465 | 6.51e-19 | 5.45e-17 | 2.79e-17 | 191 |
| hsa0496233 | Esophagus | ESCC | Vasopressin-regulated water reabsorption | 33/4205 | 44/8465 | 5.27e-04 | 1.78e-03 | 9.13e-04 | 33 |
| hsa0513230 | Oral cavity | OSCC | Salmonella infection | 174/3704 | 249/8465 | 2.67e-17 | 1.49e-15 | 7.58e-16 | 174 |
| hsa049626 | Oral cavity | OSCC | Vasopressin-regulated water reabsorption | 29/3704 | 44/8465 | 2.47e-03 | 6.52e-03 | 3.32e-03 | 29 |
| hsa05132114 | Oral cavity | OSCC | Salmonella infection | 174/3704 | 249/8465 | 2.67e-17 | 1.49e-15 | 7.58e-16 | 174 |
| hsa0496213 | Oral cavity | OSCC | Vasopressin-regulated water reabsorption | 29/3704 | 44/8465 | 2.47e-03 | 6.52e-03 | 3.32e-03 | 29 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DYNC2LI1 | SNV | Missense_Mutation | novel | c.657N>T | p.Met219Ile | p.M219I | Q8TCX1 | protein_coding | tolerated(0.92) | benign(0.003) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| DYNC2LI1 | SNV | Missense_Mutation | novel | c.980N>A | p.Arg327Lys | p.R327K | Q8TCX1 | protein_coding | deleterious(0.04) | possibly_damaging(0.791) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DYNC2LI1 | SNV | Missense_Mutation | novel | c.506N>T | p.Pro169Leu | p.P169L | Q8TCX1 | protein_coding | deleterious(0.04) | probably_damaging(0.992) | TCGA-S3-AA11-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | CR |
| DYNC2LI1 | SNV | Missense_Mutation | novel | c.436G>C | p.Gly146Arg | p.G146R | Q8TCX1 | protein_coding | tolerated(0.41) | benign(0.015) | TCGA-ZJ-AB0I-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| DYNC2LI1 | SNV | Missense_Mutation | c.373N>G | p.Pro125Ala | p.P125A | Q8TCX1 | protein_coding | tolerated(0.51) | benign(0.012) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DYNC2LI1 | SNV | Missense_Mutation | novel | c.514C>T | p.His172Tyr | p.H172Y | Q8TCX1 | protein_coding | tolerated(0.6) | benign(0) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DYNC2LI1 | SNV | Missense_Mutation | c.1013N>C | p.Lys338Thr | p.K338T | Q8TCX1 | protein_coding | deleterious(0) | possibly_damaging(0.793) | TCGA-AA-3956-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| DYNC2LI1 | SNV | Missense_Mutation | c.388C>A | p.Leu130Ile | p.L130I | Q8TCX1 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| DYNC2LI1 | SNV | Missense_Mutation | c.582N>G | p.Asp194Glu | p.D194E | Q8TCX1 | protein_coding | tolerated(0.6) | benign(0.02) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| DYNC2LI1 | SNV | Missense_Mutation | c.791N>A | p.Ser264Tyr | p.S264Y | Q8TCX1 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |